Clinical Trials - MOPH Qatar Diabetes Newsletter - 28th Feb 2018

    View this newsletter in full

Novo's pioneering diabetes pill impresses in its first big study

The world's largest diabetes drugmaker, Novo Nordisk, presented the first successful data from a large final-stage study of a pill it hopes will transform the diabetes market. The oral form of the drug, known generically as semaglutide, is crucial for ensuring the group's long-term growth, as price pressure mounts in a crowded market targeting the world's 450 million diabetics.
22nd Feb 2018 - CNBC

Pioneering Diabetes Pill Impressive in Study

22nd Feb 2018 - Newsmax

Novo's pioneering diabetes pill impresses in first big study

23rd Feb 2018 - Asian Age

Novo Nordisk study highlight benefits of new type 2 diabetes therapy

26th Feb 2018 - Zenopa

Trulicity Aids Diabetes Control When Added to an SGLT-2 Inhibitor

Dulaglutide (Trulicity, Eli Lilly and Company) significantly improved HbA1C when added to ongoing type-2 diabetes treatment with a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, according to results from the phase 3b AWARD-10 trial. The data were published online in The Lancet Diabetes & Endocrinology and released by Lilly. Dulaglutide is a once-weekly, injectable glucagon-like peptide-1 (GLP-1) receptor agonist approved to improve blood glucose in adults with type-2 diabetes.
26th Feb 2018 - P&T Community

Hypertension drug could prevent the onset of Type 1 diabetes, study says

A study published in the Journal of Clinical Investigation has revealed that a common drug used to treat hypertension is capable of preventing the onset of type 1 diabetes. The drug, methyldopa has been used for treating hypertension among pregnant women and children for many years, and this new study conducted by researchers at the University of Colorado has indicated that this drug can be used for treating diabetes as well. "We can now predict with almost 100 percent accuracy who is likely to get type 1 diabetes. The goal with this drug is to delay or prevent the onset of the disease among those at risk," said Aaron Michels from the University of Colorado, reports Science Daily.
18th Feb 2018 - International Business Times Singapore